key: cord-0828549-jhxl7ral
authors: Campo, Isabela; Meza Corso, María Fernanda; Cárdenas, Paola; Castro, Juan Raúl; González, Cesar; Cortés, Carolina; Franco, Manuel; Valenzuela, Fernando
title: COVID-19 in Psoriasis patients. A Latin American case series.
date: 2021-09-11
journal: JAAD Int
DOI: 10.1016/j.jdin.2021.09.001
sha: 8c26c132d19eb003a97c3b60031f58efe2564fbb
doc_id: 828549
cord_uid: jhxl7ral

nan

The coexistence of conditions other than psoriasis that potentially constitute a risk for 60 hospitalization 1,4 were hypertension (46.66%) obesity (6.66%) and chronic liver disease (20%). 61

Comorbidities such as cardiovascular disease and chronic lung disease, as other studies have 62 described, were less frequent. 1,3 Our findings are consistent with those previously reported in other 63 case series in Italy. 5 Further studies are required to establish whether these comorbidities increase 64 the risk of COVID-19 severity and hospital admission rates in patients with psoriasis. 65

This case series had a limited number of patients but is of great value in our population because of 66 the absence of major real-life follow-up data. Our data suggest that negative outcomes during acute 67 infection occur less frequently than expected, especially in patients receiving biological therapies. 68

Hospitalization rate was lower in patients with biologic therapy as was described in other case series 69 in New York 3 . This could be related to the main problem in COVID-19 complications being associated 70 with a "cytokine storm"; immunosuppressive therapies could maybe reduce this process, but 71 further studies are required to stablish whether is a protective factor. Importantly, these 72 observational data are subject to important biases, and cannot be used to determinate true 73 population-level outcomes. 74 1. Mahil The coexistence of conditions other than psoriasis that potentially constitute a risk for 140 hospitalization 1,4 were hypertension (46.66%) obesity (6.66%) and chronic liver disease (20%). 141

Comorbidities such as cardiovascular disease and chronic lung disease, as other studies have 142 described, were less frequent. 1,3 Our findings are consistent with those previously reported in other 143 case series in Italy. 5 Further studies are required to establish whether these comorbidities increase 144 the risk of COVID-19 severity and hospital admission rates in patients with psoriasis. 145

This case series had a limited number of patients but is of great value in our population because of 146 the absence of major real-life follow-up data. Our data suggest that negative outcomes during acute 147 infection occur less frequently than expected, especially in patients receiving biological therapies. 148

Hospitalization rate was lower in patients with biologic therapy as was described in other case series 149 in New York 3 . This could be related to the main problem in COVID-19 complications being associated 150 with a "cytokine storm"; immunosuppressive therapies could maybe reduce this process, but 151 further studies are required to stablish whether is a protective factor. Importantly, these 152 observational data are subject to important biases, and cannot be used to determinate true 153 population-level outcomes. 154 

Factors associated with 159 adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-160 based study

Biologics increase the risk of SARS-CoV-2 infection and 162 hospitalization, but not ICU admission and death: Real-life data from a large cohort during 163 red-zone declaration

Mediated Inflammatory Diseases -Case Series from New York

Clinical course and risk factors for mortality of 168 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

The impact of the COVID-171 19 pandemic on patients with chronic plaque psoriasis being treated with biological 172 therapy: the Northern Italy experience